RecruitingNCT05589974

Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy


Sponsor

Helse Stavanger HF

Enrollment

50 participants

Start Date

Oct 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria11

  • Able to sign informed consent
  • Possible to obtain fundus imaging
  • Acute CSC ˂4 months of duration in one eye, defined as:
  • Subfoveal presence of SRF on OCT
  • Present attack is 1st -3rd attack of CSC
  • b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT
  • Chronic CSC ≥4 months of duration in one eye, defined as:
  • Subfoveal presence of SRF on OCT
  • Subjective visual loss/symptoms
  • Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT
  • Patient history and examination consistent with chronic CSC

Exclusion Criteria2

  • History of retinal disease other than CSC (e.g. retinal detachment)
  • Contraindications for FA, ICGA or PDT (only for chronic CSC)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVerteporfin

Chronic CSC are receiving one treatment before the observation period.


Locations(1)

Stavanger University Hospital, Department of Ophthalmology

Stavanger, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05589974


Related Trials